TW318850B - - Google Patents

Download PDF

Info

Publication number
TW318850B
TW318850B TW084111436A TW84111436A TW318850B TW 318850 B TW318850 B TW 318850B TW 084111436 A TW084111436 A TW 084111436A TW 84111436 A TW84111436 A TW 84111436A TW 318850 B TW318850 B TW 318850B
Authority
TW
Taiwan
Prior art keywords
aryl
alkyl
group
hydrogen
compound
Prior art date
Application number
TW084111436A
Other languages
English (en)
Chinese (zh)
Inventor
Louis Plamondon
Original Assignee
Proscript Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26987313&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW318850(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Proscript Inc filed Critical Proscript Inc
Application granted granted Critical
Publication of TW318850B publication Critical patent/TW318850B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
TW084111436A 1994-10-28 1995-10-27 TW318850B (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33052594A 1994-10-28 1994-10-28
US08/442,581 US6083903A (en) 1994-10-28 1995-05-16 Boronic ester and acid compounds, synthesis and uses

Publications (1)

Publication Number Publication Date
TW318850B true TW318850B (enExample) 1997-11-01

Family

ID=26987313

Family Applications (1)

Application Number Title Priority Date Filing Date
TW084111436A TW318850B (enExample) 1994-10-28 1995-10-27

Country Status (24)

Country Link
US (16) US6083903A (enExample)
EP (4) EP0788360B3 (enExample)
JP (1) JP3717934B2 (enExample)
KR (1) KR100398944B1 (enExample)
CN (2) CN101077875B (enExample)
AT (3) ATE411324T1 (enExample)
AU (1) AU710564B2 (enExample)
CA (2) CA2496538C (enExample)
CH (1) CH0788360H1 (enExample)
CY (1) CY2484B1 (enExample)
DE (5) DE69535866D1 (enExample)
DK (3) DK1312609T3 (enExample)
ES (3) ES2199257T7 (enExample)
FI (2) FI114801B (enExample)
FR (1) FR04C0014I2 (enExample)
IL (5) IL115790A (enExample)
LU (1) LU91083I2 (enExample)
MX (1) MX9703063A (enExample)
NL (1) NL300151I2 (enExample)
NO (2) NO310558B1 (enExample)
NZ (2) NZ337211A (enExample)
PT (3) PT788360E (enExample)
TW (1) TW318850B (enExample)
WO (1) WO1996013266A1 (enExample)

Families Citing this family (307)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6838477B2 (en) * 1995-04-12 2005-01-04 President And Fellows Of Harvard College Lactacystin analogs
FR2758329B1 (fr) * 1997-01-16 1999-02-12 Synthelabo Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
PT979096E (pt) 1997-02-15 2003-09-30 Millennium Pharm Inc Tratamento de enfartes atraves da inibicao de nf-kb
US6221888B1 (en) * 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
EP1017398A1 (en) * 1997-09-25 2000-07-12 Proscript, Inc. Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-kb via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases
BR9813233A (pt) * 1997-09-29 2000-08-22 Point Therapeutics Inc Estimulação de células hematopoéticas in vitro
US6831057B2 (en) * 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
CA2219867A1 (en) * 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
DE19802450A1 (de) * 1998-01-23 1999-07-29 Hoechst Marion Roussel De Gmbh Ustilipide, Verfahren zu deren Herstellung sowie deren Verwendung
US6075150A (en) * 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6902721B1 (en) * 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6838436B1 (en) * 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6979697B1 (en) * 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
EP0982317A1 (en) * 1998-08-26 2000-03-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalent inhibitors of the proteasome
WO2000023614A1 (en) * 1998-10-20 2000-04-27 Millennium Pharmaceuticals, Inc. Method for monitoring proteasome inhibitor drug action
US6492333B1 (en) 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US6649593B1 (en) * 1999-10-13 2003-11-18 Tularik Inc. Modulators of SREBP processing
US20040039129A1 (en) * 2000-08-16 2004-02-26 Hall Dennis G. Non-pressurized methods for the preparation of conjugrated solid supports for boronic acids
US6919382B2 (en) 2000-08-31 2005-07-19 The Governors Of The University Of Alberta Preparation and uses of conjugated solid supports for boronic acids
WO2002030455A2 (de) * 2000-10-12 2002-04-18 Viromics Gmbh Mittel zur behandlung von virus-infektionen
US6699835B2 (en) * 2001-01-25 2004-03-02 The United States Of America As Represented By The Department Of Health And Human Services Formulation of boronic acid compounds
DE60218153T2 (de) 2001-05-21 2007-06-28 Alcon Inc. Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
US7112588B2 (en) * 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
DE60209227T2 (de) * 2001-05-30 2006-08-17 Novartis Ag 2-((n-(2-amino-3-(heteroaryl- oder -aryl)propionyl)aminoacyl)amino)-alkylboronsäurederivate
JPWO2003033506A1 (ja) * 2001-10-12 2005-02-03 杏林製薬株式会社 アミノボラン酸誘導体およびそれを含有するプロテアソーム阻害薬
JPWO2003033507A1 (ja) * 2001-10-12 2005-02-03 杏林製薬株式会社 ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
US7524883B2 (en) 2002-01-08 2009-04-28 Eisai R&D Management Co., Ltd. Eponemycin and epoxomicin analogs and uses thereof
WO2003077928A1 (en) * 2002-03-12 2003-09-25 Ariad Pharmaceuticals, Inc. Peptide analogues and uses thereof
ES2322950T3 (es) 2002-03-13 2009-07-02 Janssen Pharmaceutica Nv Derivados de aminocarbonilo como nuevos inhibidores de histona-desacetilasa.
BR0307607A (pt) 2002-03-13 2004-12-21 Janssen Pharmaceutica Nv Derivados de carbonilamino como inibidores de histona desacetilase
AU2003218735B2 (en) * 2002-03-13 2009-03-12 Janssen Pharmaceutica N.V. Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
CA2476186C (en) 2002-03-13 2011-07-19 Janssen Pharmaceutica N.V. Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
DE50313092D1 (de) * 2002-04-05 2010-10-28 Virologik Gmbh Mittel zur behandlung von flaviviridae-infektionen
AU2003243594A1 (en) * 2002-06-13 2003-12-31 Johns Hopkins University Novel boronic chalcone derivatives and uses thereof
IL166157A0 (en) * 2002-07-09 2006-01-15 Point Therapeutics Inc Methods and compositions relating to isoleucine boroproline compounds
AU2003271747B2 (en) * 2002-08-14 2008-09-11 Janssen Pharmaceutica N.V. Use of NF-kappa B inhibitors for the treatment of mastitis
US20050282757A1 (en) * 2002-09-09 2005-12-22 Trigen Limited Peptide boronic acid compounds useful in anticoagulation
US20060084592A1 (en) * 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
US20050119226A1 (en) * 2003-09-09 2005-06-02 Trigen Limited Methods for synthesizing organoboronic compounds and products thereof
US7112572B2 (en) * 2002-09-09 2006-09-26 Trigen Limited Multivalent metal salts of boronic acids
DE60317039T2 (de) * 2002-09-09 2008-07-31 Trigen Ltd. Peptidborsäuren und deren Verwendung in der Herstellung von Salzen derselben
US20050176651A1 (en) * 2002-09-09 2005-08-11 Trigen Limited Peptide boronic acids useful in making salts thereof
EP1542768A1 (en) * 2002-09-20 2005-06-22 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
JP5717937B2 (ja) 2002-12-06 2015-05-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害療法を用いた患者の同定、判定および治療方法
CN100341880C (zh) * 2003-02-13 2007-10-10 上海仁虎制药股份有限公司 新型硼酸或硼酸酯类化合物、制备方法及在药学上的应用
US20070110785A1 (en) * 2003-07-03 2007-05-17 Eugene Tedeschi Medical devices with proteasome inhibitors for the treatment of restenosis
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7223745B2 (en) * 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
MXPA06005104A (es) 2003-11-05 2007-01-25 Palingen Inc Citotoxicidad de celulas b aumentada en anticuerpos de enlace a cdim.
US20060052390A1 (en) * 2003-12-24 2006-03-09 Scios, Inc. Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
US20050203027A1 (en) * 2004-02-23 2005-09-15 Trustees Of Tufts College Inhibitors of dipeptidylpeptidase IV
GB0405272D0 (en) * 2004-03-09 2004-04-21 Trigen Ltd Compounds
US7371875B2 (en) * 2004-03-12 2008-05-13 Miikana Therapeutics, Inc. Cytotoxic agents and methods of use
EP2377868A1 (en) 2004-03-30 2011-10-19 Millennium Pharmaceuticals, Inc. Synthesis of Bortezomib
AU2016202747B2 (en) * 2004-03-30 2017-11-23 Millennium Pharmaceuticals, Inc. Synthesis of boronic ester and acid compounds
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
BRPI0509879A (pt) 2004-04-15 2007-10-16 Proteolix Inc compostos para inibição enzimática
DK2030981T3 (da) 2004-05-10 2014-10-13 Onyx Therapeutics Inc Forbindelser til proteasom-enzymhæmning
EP1765313A2 (en) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
CA2574418A1 (en) 2004-07-23 2006-02-02 Susan Marie Royalty Peptidase inhibitors
CA2572833C (en) 2004-07-28 2013-04-09 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
EP2100899A3 (en) 2004-10-20 2009-09-30 Proteolix, Inc. Compounds for proteasome enzyme inhibition
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
AU2005304973A1 (en) 2004-11-05 2006-05-18 Palingen, Inc. Antibody induced cell membrane wounding
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
US20070098685A1 (en) * 2005-01-19 2007-05-03 Brand Stephen J Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
US20090036435A1 (en) 2005-01-21 2009-02-05 Astex Therapeutics Limited Pharmaceutical Compounds
CA2595749A1 (en) * 2005-01-27 2006-08-03 Research Development Foundation Combination therapy with triterpenoid compounds and proteasome inhibitors
US7468383B2 (en) * 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7767657B2 (en) 2005-02-16 2010-08-03 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
SI2343304T1 (sl) 2005-02-16 2015-08-31 Anacor Pharmaceuticals, Inc. Biocidne boroftalidne spojine
WO2006099261A2 (en) * 2005-03-11 2006-09-21 The University Of North Carolina At Chapel Hill Potent and specific immunoproteasome inhibitors
AU2006242446A1 (en) * 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor
US8138198B2 (en) 2005-05-18 2012-03-20 Angibaud Patrick Rene Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
AU2006202209B2 (en) * 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
WO2006133052A2 (en) * 2005-06-08 2006-12-14 Centocor, Inc. A cellular therapy for ocular degeneration
US20090017006A1 (en) * 2005-07-06 2009-01-15 Biodevelops Pharma Entwicklung Gmbh Use of a compound for enhancing the expression of membrane proteins on the cell surface
EP1752467A1 (en) 2005-08-10 2007-02-14 4Sc Ag Inhibitors of cancer cell, t-cell and keratinocyte proliferation
US7531517B2 (en) 2005-08-10 2009-05-12 4Sc Ag Inhibitors of cancer cell, T-cell and keratinocyte proliferation
US20070059382A1 (en) * 2005-09-09 2007-03-15 Board Of Regents, Univ. And Comm. College System Of Nevada... Medical treatment of breast cancer with boric acid materials
CN105237621A (zh) 2005-11-09 2016-01-13 欧尼斯治疗公司 用于酶抑制的化合物
EP1956908A2 (en) * 2005-12-08 2008-08-20 Cytokinetics, Inc. Certain compositions and methods of treatment
JP5137848B2 (ja) * 2006-01-19 2013-02-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼのインヒビターとしてのピリジン及びピリミジン誘導体
DK1979326T3 (da) 2006-01-19 2013-01-07 Janssen Pharmaceutica Nv Pyridin- og pyrimidinderivater som inhibitorer af histondeacetylase
AU2007206950B2 (en) * 2006-01-19 2012-02-02 Janssen Pharmaceutica N.V. Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
PL1981874T3 (pl) * 2006-01-19 2009-10-30 Janssen Pharmaceutica Nv Pochodne aminofenylowe jako nowe inhibitory deacetylazy histonowej
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
BRPI0708051A2 (pt) * 2006-02-16 2011-05-17 Anacor Pharmaceuticals Inc moléculas pequenas contendo boro como agentes antiflamatórios
TW200808739A (en) * 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
DE102006026464A1 (de) 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
WO2007143600A2 (en) * 2006-06-05 2007-12-13 Incyte Corporation Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
KR101441703B1 (ko) 2006-06-19 2014-09-17 오닉스 세라퓨틱스, 인크. 프로테아좀 저해를 위한 펩티드 에폭시케톤
CN101516375B (zh) * 2006-09-15 2012-10-03 詹森药业有限公司 类别-i具体组织蛋白脱乙酰基酶抑制剂与蛋白酶体抑制剂的组合
CA2659070C (en) * 2006-09-15 2014-10-21 Janssen Pharmaceutica Nv Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
AU2007221966A1 (en) * 2006-12-08 2008-06-26 Centenary Institute Of Cancer Medicine And Cell Biology Assay for response to proteasome inhibitors
JO3396B1 (ar) 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
US9080145B2 (en) * 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
CN101952415B (zh) 2007-07-31 2017-06-27 生命扫描有限公司 人胚胎干细胞的分化
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
JP2010535708A (ja) 2007-08-03 2010-11-25 ビオマリン アイジーエー リミテッド デュシェンヌ型筋ジストロフィーの治療のための薬物併用
AU2016253697A1 (en) * 2007-08-06 2016-11-24 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
UA97536C2 (en) * 2007-08-06 2012-02-27 Милленниум Фармасьютикалз, Инк. Proteasome inhibitors
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
EA034601B1 (ru) * 2007-08-06 2020-02-25 Милленниум Фармасьютикалз, Инк. Способ получения бороновых кислот
EP2185159A4 (en) * 2007-09-12 2012-02-08 Reddys Lab Ltd Dr BORTEZOMIB AND MANUFACTURING METHOD THEREFOR
US20090076031A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bortezomib
EA018973B1 (ru) 2007-10-04 2013-12-30 Оникс Терапьютикс, Инк. Кристаллические пептидные кето-эпоксидные ингибиторы протеаз и синтез кето-эпоксидов аминокислот
US7838673B2 (en) * 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
US20090110688A1 (en) * 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
ATE523585T1 (de) * 2007-11-27 2011-09-15 Lifescan Inc Differenzierung menschlicher embryonaler stammzellen
CN101220048B (zh) * 2007-12-14 2012-08-15 江苏先声药物研究有限公司 ZnCl2催化下的蒎烷二醇酯的制备方法
AR069798A1 (es) 2007-12-20 2010-02-17 Novartis Ag Derivados de 1, 3-tiazol, metodos para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la manufactura de medicamentos para el tratamiento de enfermedades mediadas por la fosfatidilinositol 3-cinasa.
EP2254990B1 (en) 2008-02-21 2020-04-15 Janssen Biotech, Inc. Methods, surface modified plates and compositions for cell attachment, cultivation and detachment
NZ587955A (en) 2008-03-06 2012-10-26 Anacor Pharmaceuticals Inc Boron-containing small molecules as anti-inflammatory agents
EP2285384A4 (en) * 2008-05-12 2012-04-25 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
MX349769B (es) 2008-06-17 2017-08-11 Millennium Pharm Inc Compuestos de éster boronato y composiciones farmacéuticas de los mismos.
KR20180018839A (ko) 2008-06-30 2018-02-21 얀센 바이오테크 인코포레이티드 만능 줄기 세포의 분화
CN101638414B (zh) * 2008-07-30 2014-01-08 江苏先声药物研究有限公司 肽硼酸及其酯类化合物、制备方法及其用途
US20100028307A1 (en) * 2008-07-31 2010-02-04 O'neil John J Pluripotent stem cell differentiation
US8461336B2 (en) 2008-09-04 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
EP2348863A4 (en) * 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
WO2010045503A1 (en) * 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
PE20120059A1 (es) 2008-10-21 2012-02-27 Onyx Therapeutics Inc Combinaciones farmaceuticas con epoxicetonas peptidicas
CN102272291B (zh) 2008-10-31 2018-01-16 詹森生物科技公司 人胚胎干细胞向胰腺内分泌谱系的分化
BRPI0919883A2 (pt) * 2008-10-31 2015-08-11 Centocor Ortho Biotech Inc Diferenciação de células-tronco embrionárias humanas para a linhagem endócrina pancreática
BRPI0921996A2 (pt) * 2008-11-20 2015-08-18 Centocor Ortho Biotech Inc Métodos e composições para cultura e ligação de células em substratos planos.
EP2366021B1 (en) 2008-11-20 2017-08-02 Janssen Biotech, Inc. Pluripotent stem cell culture on micro-carriers
CN101747354B (zh) * 2008-12-04 2014-08-13 江苏先声药物研究有限公司 一类β氨基酸组成的二肽硼酸及其酯类化合物、制备方法及其用途
US8461364B2 (en) * 2008-12-17 2013-06-11 Glaxosmithkline Llc Polymorphs of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[C][1,2]oxaborol-1-OL
KR20110114562A (ko) 2009-01-09 2011-10-19 썬 파마 어드밴스트 리서치 컴패니 리미티드 보르테조밉 함유 약학적 조성물
WO2010096574A1 (en) 2009-02-20 2010-08-26 Lisanti Michael P A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
EP2405916B1 (en) 2009-03-12 2018-02-07 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
WO2010106135A1 (en) 2009-03-20 2010-09-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combined use for the treatment of ovarian carcinoma
HRP20150948T1 (hr) * 2009-03-24 2015-10-09 Janssen Pharmaceutica N.V. Biomarkeri za procjenjivanje perifernog neuropatskog odgovora na lijeäśenje sa inhibitorom proteazoma
WO2010114770A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
WO2010114768A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-epothilone conjugates, particles, compositions, and related methods of use
AU2010234916A1 (en) * 2009-03-30 2011-10-13 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
MX2011012538A (es) * 2009-05-27 2012-02-08 Cephalon Inc Terapia de combinacion para el tratamiento del mieloma multiple.
CN101928329B (zh) 2009-06-19 2013-07-17 北京大学 三肽硼酸(酯)类化合物、其制备方法和应用
EP2443128B1 (en) 2009-06-19 2017-12-20 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters
EP2270019A1 (en) 2009-06-19 2011-01-05 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters
EP2280016A1 (en) 2009-07-27 2011-02-02 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters via substituted alk-1-ynes
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
DE102009027754A1 (de) 2009-07-15 2011-05-05 Schubert, Ulrich, Dr. Verfahren zur Hemmung der Reifung von dendritischen Zellen
MX348077B (es) 2009-07-20 2017-05-25 Janssen Biotech Inc Diferenciacion de celulas madre embrionarias humanas.
MX340952B (es) * 2009-07-20 2016-07-29 Janssen Biotech Inc Diferenciacion de celulas madre embrionarias humanas.
MX2012000898A (es) 2009-07-20 2012-06-01 Janssen Biotech Inc Diferenciacion de celulas madre embrionarias humanas.
JP2013500974A (ja) * 2009-07-28 2013-01-10 アナコール ファーマシューティカルズ，インコーポレイテッド 三置換ホウ素含有分子
US9440994B2 (en) * 2009-08-14 2016-09-13 Anacor Pharmaceuticals, Inc. Boron containing small molecules as antiprotozoal agents
WO2011022502A1 (en) 2009-08-18 2011-02-24 Georgetown University Boronic acid compositions and methods related to cancer
US20110207701A1 (en) * 2009-08-19 2011-08-25 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
JP5567136B2 (ja) 2009-09-08 2014-08-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ４−置換ピリジン−３−イル−カルボキサミド化合物及び使用方法
WO2011037731A1 (en) * 2009-09-25 2011-03-31 Anacor Pharmaceuticals, Inc. Boron containing small molecules
EP2305285A1 (en) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Means and methods for treating ischemic conditions
WO2011038924A2 (en) 2009-10-01 2011-04-07 Janssen Pharmaceutica Nv Treatment of disease with proteasome inhibitors
US9346834B2 (en) 2009-10-20 2016-05-24 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011060196A1 (en) * 2009-11-11 2011-05-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
CN102725300B (zh) * 2009-12-22 2015-03-11 赛福伦公司 蛋白酶体抑制剂及其制备、纯化、和应用的方法
SG10201408552YA (en) 2009-12-23 2015-02-27 Janssen Biotech Inc Differentiation of human embryonic stem cells
KR101764404B1 (ko) 2009-12-23 2017-08-03 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
WO2011090940A1 (en) 2010-01-19 2011-07-28 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US8716478B2 (en) 2010-01-27 2014-05-06 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
RU2702198C2 (ru) * 2010-03-01 2019-10-04 Янссен Байотек, Инк. Способы очистки клеток, производных от плюрипотентных стволовых клеток
AU2011223795B2 (en) 2010-03-01 2015-11-05 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
JP5661912B2 (ja) * 2010-03-18 2015-01-28 イノファーマ，インコーポレイテッド 安定なボルテゾミブ製剤
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
US8623911B2 (en) 2010-03-19 2014-01-07 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agent
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CN102892291A (zh) 2010-03-31 2013-01-23 米伦纽姆医药公司 1-氨基-2-环丙基乙硼酸衍生物
AU2013204868B2 (en) * 2010-03-31 2016-10-13 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
CA2795559A1 (en) 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
CN101812026B (zh) * 2010-04-12 2013-08-28 亚邦医药股份有限公司 一种硼替佐米的合成方法
WO2011133479A2 (en) 2010-04-19 2011-10-27 Niiki Pharma Inc. Combination therapy with a proteasome inhibitor and a gallium complex
US8809282B2 (en) 2010-05-06 2014-08-19 Duke University Method of reducing titers of antibodies specific for a therapeutic agent
BR112012028855A2 (pt) 2010-05-12 2015-09-22 Janssen Biotech Inc diferenciação das células-tronco embrionárias humanas
CN105797168A (zh) 2010-05-18 2016-07-27 天蓝制药公司 用于治疗自身免疫性疾病或其它疾病的组合物和方法
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
SG10201506852VA (en) 2010-08-31 2015-10-29 Janssen Biotech Inc Differentiation of human embryonic stem cells
KR101851956B1 (ko) 2010-08-31 2018-04-25 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
RU2599420C2 (ru) 2010-08-31 2016-10-10 Янссен Байотек, Инк. Дифференцирование плюрипотентных стволовых клеток
BR112013005426B1 (pt) 2010-09-07 2021-08-24 Anacor Pharmaceuticals, Inc Composto, composição, combinação, e, formulação farmacêutica
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
EP2624818B1 (en) 2010-10-05 2017-04-05 Fresenius Kabi USA, LLC Bortezomib formulations stabilised with boric acid
WO2012048745A1 (en) 2010-10-14 2012-04-19 Synthon Bv Process for making bortezomib and intermediates for the process
PE20140293A1 (es) 2011-01-31 2014-03-19 Novartis Ag Novedosos derivados heterociclicos
TW201309303A (zh) * 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑
WO2012135528A2 (en) 2011-03-29 2012-10-04 Texas Tech University System Galectin-3c combination therapy for human cancer
BR112013025005A2 (pt) 2011-03-31 2017-01-17 Nanocarrier Co Ltd composição farmacêutica contendo copolímero por blocos compreendendo composto de ácido borônico
WO2012170765A2 (en) 2011-06-10 2012-12-13 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
JP5944986B2 (ja) * 2011-06-22 2016-07-05 セファロン、インク． プロテアソーム阻害剤、ならびにそれらの調製、精製、および使用のためのプロセス
US8481655B2 (en) 2011-07-27 2013-07-09 Wacker Chemical Corporation Copper complexes of amino-functional organosilicon compounds and their use
WO2013021032A1 (en) 2011-08-11 2013-02-14 Janssen Pharmaceutica Nv Histone deacetylase inhibitors in combination with proteasome inhibitors and dexamethasone
MX357429B (es) 2011-08-11 2018-07-09 Janssen Pharmaceutica Nv Predictores para el tratamiento del cáncer.
SI2744332T1 (sl) 2011-08-19 2017-01-31 Glaxo Group Limited Benzofuranske spojine za zdravljenje infekcij z virusom hepatitisa C
WO2013033396A2 (en) * 2011-08-30 2013-03-07 Trustees Of Tufts College Fap-activated proteasome inhibitors for treating solid tumors
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2587533T3 (es) 2011-10-28 2016-10-25 Novartis Ag Derivados de purina y su uso en el tratamiento de enfermedades
US9827246B2 (en) 2011-10-28 2017-11-28 Millennium Pharmaceuticals, Inc. Biomarkers of response to NAE inhibitors
EP2776586B1 (en) 2011-11-11 2018-03-07 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
CA2855356A1 (en) 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
US9114177B2 (en) 2011-11-17 2015-08-25 The University Of Tokyo Block copolymer having phenylboronic acid group introduced therein, and use thereof
RU2705001C2 (ru) 2011-12-22 2019-11-01 Янссен Байотек, Инк. Дифференцировка эмбриональных стволовых клеток человека в одногормональные инсулинположительные клетки
WO2013110005A1 (en) 2012-01-18 2013-07-25 Wisconsin Alumni Research Foundation Boronate-mediated delivery of molecules into cells
US9732101B2 (en) 2012-01-18 2017-08-15 Wisconsin Alumni Research Foundation Bioreversible boronates for delivery of molecules into cells
CA2862492A1 (en) 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
GB2523211B (en) 2012-01-27 2020-03-18 Univ Jefferson MCT protein inhibitor-related prognostic and therapeutic methods
ES2735289T3 (es) 2012-02-08 2019-12-17 Igm Biosciences Inc Proteínas de unión a cdim y usos de las mismas
EP2819673B1 (en) 2012-03-02 2016-09-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions comprising boronic acid compounds
KR20140131999A (ko) 2012-03-07 2014-11-14 얀센 바이오테크 인코포레이티드 만능 줄기 세포의 증폭 및 유지를 위한 한정 배지
CA2784240C (en) 2012-03-27 2014-07-08 Innopharma, Inc. Stable bortezomib formulations
SG11201406550QA (en) 2012-05-16 2014-11-27 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
CN108103006A (zh) 2012-06-08 2018-06-01 詹森生物科技公司 人胚胎干细胞向胰腺内分泌细胞的分化
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
JP2013006855A (ja) * 2012-09-03 2013-01-10 Millennium Pharmaceuticals Inc プロテアソーム阻害剤
RU2015112190A (ru) * 2012-09-11 2016-11-10 Сипла Лимитед Способ получения бортезомиба
US10662477B2 (en) 2012-10-01 2020-05-26 Millennium Pharmaceuticals, Inc. Biomarkers and methods to predict response to inhibitors and uses thereof
WO2014072985A1 (en) 2012-11-06 2014-05-15 Natco Pharma Limited Novel boronic acid derivatives as anti cancer agents
JP2015536342A (ja) 2012-11-16 2015-12-21 シルパ・メディケア・リミテッドＳｈｉｌｐａ Ｍｅｄｉｃａｒｅ Ｌｉｍｉｔｅｄ 結晶ボルテゾミブの方法
WO2014097306A1 (en) 2012-12-21 2014-06-26 Natco Pharma Limited Stable and pure polymorphic form of bortezomib
CA2896750A1 (en) 2012-12-31 2014-07-03 Janssen Biotech, Inc. Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells
US10344264B2 (en) 2012-12-31 2019-07-09 Janssen Biotech, Inc. Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
KR101942769B1 (ko) 2012-12-31 2019-01-28 얀센 바이오테크 인코포레이티드 Hb9 조절제를 사용하는 인간 배아 줄기세포의 췌장 내분비 세포로의 분화
SMT201900585T1 (it) 2013-03-13 2019-11-13 Forma Therapeutics Inc Derivati di 2-idrossi-1-4-[(4-fenilfenil)carbonil]piperazin-1-iletan-1-one e composti correlati come inibitori di acido grasso sintetasi (fasn) per il trattamento del cancro
WO2014170628A1 (en) 2013-04-16 2014-10-23 Cipla Limited Process for the preparation of bortezomib mannitol ester
EP2986290A4 (en) 2013-04-19 2017-01-04 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US10478445B2 (en) 2013-07-03 2019-11-19 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
WO2015051067A1 (en) 2013-10-03 2015-04-09 Millennium Pharmaceuticals, Inc. Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
CN104586776B (zh) * 2013-10-30 2017-05-17 扬子江药业集团上海海尼药业有限公司 以硼替佐米为活性成分的制剂及其制备方法
JP6468562B2 (ja) * 2013-11-21 2019-02-13 国立大学法人北海道大学 プロテアソーム阻害性化合物
US10191033B2 (en) 2013-12-05 2019-01-29 The Broad Institute, Inc. Biomarkers for detecting pre-cachexia or cachexia and methods of treatment thereof
EP4000619A1 (en) 2013-12-06 2022-05-25 Novartis AG Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
US10167311B2 (en) 2014-02-03 2019-01-01 Ohio State Innovation Foundation Boronic acid esters and pharmaceutical formulations thereof
EP2910557A1 (en) * 2014-02-20 2015-08-26 Ikerchem, S.L. Enantiopure tetrasubstituted pyrrolidines as scaffolds for proteasome inhibitors and medicinal applications thereof
EP3141243B1 (en) 2014-05-08 2020-07-08 The University of Tokyo Pharmaceutical composition
AU2015259573B2 (en) 2014-05-16 2021-03-18 Janssen Biotech, Inc. Use of small molecules to enhance MAFA expression in pancreatic endocrine cells
SG10202003693RA (en) 2014-05-20 2020-05-28 Millennium Pharm Inc Boron-containing proteasome inhibitors for use after primary cancer therapy
EP3177292B1 (en) 2014-08-07 2020-11-25 Mayo Foundation for Medical Education and Research Compounds and methods for treating cancer
RU2017115191A (ru) * 2014-10-01 2018-11-06 Мерк Патент Гмбх Производные бороновой кислоты
WO2016110870A1 (en) 2015-01-07 2016-07-14 Emcure Pharmaceuticals Limited Pharmaceutical composition of bortezomid
MA41505A (fr) 2015-02-11 2017-12-19 Millennium Pharm Inc Nouvelle forme cristalline d'un inhibiteur de protéasome
JP2018510859A (ja) 2015-03-17 2018-04-19 レオン−ナノドラッグズ ゲーエムベーハー 安定化されたボロン酸化合物を含むナノ粒子
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2016184793A1 (en) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma
WO2016205790A2 (en) 2015-06-19 2016-12-22 Hanlin Scientific, Inc. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
EP3120837A1 (de) 2015-07-22 2017-01-25 Stada Arzneimittel Ag Verfahren zur herstellung einer bortezomibester-lösung
EP3120836A1 (de) 2015-07-22 2017-01-25 Stada Arzneimittel Ag Gebrauchsfertige bortezomib-lösung
CN106478700B (zh) * 2015-08-26 2020-12-29 杭州雷索药业有限公司 硼基取代的苯胺类蛋白激酶抑制剂
CN106588965A (zh) * 2015-10-15 2017-04-26 北京大学 脲拟肽硼酸化合物及其药物组合物、制备方法和用途
US20180280370A1 (en) 2015-11-02 2018-10-04 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
WO2017106196A1 (en) 2015-12-14 2017-06-22 The Broad Institute, Inc. Compositions and methods for treating cardiac dysfunction
CN107151255A (zh) * 2016-03-06 2017-09-12 复旦大学 硼酸类化合物及其制备方法和用途
CN107151254A (zh) * 2016-03-06 2017-09-12 复旦大学 一种作为20s蛋白酶体抑制剂的硼酸类化合物及其制备方法
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
CN106008572B (zh) * 2016-05-23 2018-08-17 成都千禧莱医药科技有限公司 一类二肽硼酸化合物及制备方法和用途
US10526315B2 (en) 2016-06-21 2020-01-07 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
AU2017282651B2 (en) 2016-06-21 2021-08-12 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives
JP6681284B2 (ja) * 2016-06-23 2020-04-15 信越化学工業株式会社 糖アルコール化合物の金属低減方法
JP6223508B2 (ja) * 2016-06-27 2017-11-01 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
WO2018038687A1 (en) 2016-08-22 2018-03-01 Mustafa Nevzat Ilaç Sanayii A.Ş. Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
US20200261596A1 (en) 2016-10-20 2020-08-20 Pfizer Inc. Therapeutic Particles with Peptide Boronic Acid or Boronate Ester Compounds and Methods of Making and Using Same
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
ES2914123T3 (es) 2017-01-09 2022-06-07 Shuttle Pharmaceuticals Inc Inhibidores selectivos de la histona desacetilasa para el tratamiento de una enfermedad humana
CN110312727A (zh) 2017-02-17 2019-10-08 费森尤斯卡比肿瘤学有限公司 一种改进的制备硼酸酯的方法
US11596629B2 (en) 2017-02-28 2023-03-07 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
WO2019040680A1 (en) 2017-08-23 2019-02-28 Krzar Life Sciences IMMUNOPROTEASOME INHIBITORS AND IMMUNOSUPPRESSANT AGENT IN THE TREATMENT OF AUTOIMMUNE DISORDERS
EP3694878A1 (en) 2017-09-14 2020-08-19 GlaxoSmithKline Intellectual Property Development Limited Combination treatment for cancer
JP2018024694A (ja) * 2017-10-03 2018-02-15 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
WO2019099582A1 (en) 2017-11-16 2019-05-23 Principia Biopharma Inc. Immunoproteasome inhibitors
AU2018369787B2 (en) * 2017-11-16 2023-04-20 Principia Biopharma Inc. Immunoproteasome inhibitors
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
ES2983284T3 (es) 2018-01-09 2024-10-22 Shuttle Pharmaceuticals Inc Inhibidores selectivos de histona deacetilasa para el tratamiento de enfermedades humanas
EP3746065A4 (en) 2018-01-29 2022-02-16 Cognos Therapeutics Inc. INTRATUMORAL ADMINISTRATION OF BORTEZOMIB
WO2019178438A1 (en) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of cancer
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
EP3873214A4 (en) 2018-10-29 2022-07-13 Forma Therapeutics, Inc. Solid forms of (4-(2-fluoro-4-(1-methyl-1 h-benzo[d]imidazol-5-yl)benzoyl) piperazin-1-yl)(1-hydroxycyclopropyl)methanone
CN109824756B (zh) * 2019-03-19 2022-03-22 山东大学 含有4-(苯磺酰基)哌嗪-2-酮的苯丙氨酸衍生物及其制备方法与应用
JP2020079299A (ja) * 2020-02-18 2020-05-28 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
CN114437119B (zh) * 2020-10-30 2024-08-09 苏州开拓药业股份有限公司 一种c-Myc蛋白抑制剂及其制备方法和用途
WO2022120039A2 (en) * 2020-12-02 2022-06-09 Steven Hoffman Compositions and methods for modulating cancer in non-human mammals
EP4242213A4 (en) * 2020-12-10 2024-05-08 Lg Chem, Ltd. BORIC ACID COMPOUND
US11964993B2 (en) 2021-07-03 2024-04-23 Shilpa Pharma Lifesciences Limited Crystalline bortezomib process
EP4134083A1 (en) 2021-08-12 2023-02-15 Extrovis AG Pharmaceutical compositions of bortezomib
CN113957441B (zh) * 2021-10-29 2024-01-02 光华科学技术研究院(广东)有限公司 蚀刻液及其制备方法和应用
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
EP4522183A2 (en) 2022-05-11 2025-03-19 Celgene Corporation Methods and uses related to t cell therapy and production of same
EP4611798A1 (en) 2022-11-02 2025-09-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261868A (en) * 1979-08-08 1981-04-14 Lever Brothers Company Stabilized enzymatic liquid detergent composition containing a polyalkanolamine and a boron compound
US4369183A (en) * 1979-09-06 1983-01-18 Merck & Co., Inc. 2-Pyridyl-1,2-benzisothiazolinone-1,1-dioxides and their use as selective protease inhibitors
US4510130A (en) 1983-05-20 1985-04-09 Genetic Diagnostics Corporation Promoting animal and plant growth with leupeptin
US4537773A (en) 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4537707A (en) * 1984-05-14 1985-08-27 The Procter & Gamble Company Liquid detergents containing boric acid and formate to stabilize enzymes
US4842769A (en) * 1985-07-26 1989-06-27 Colgate-Palmolive Co. Stabilized fabric softening built detergent composition containing enzymes
US4759032A (en) 1987-06-03 1988-07-19 Monsanto Company Electrode seal assembly
US5250720A (en) * 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) * 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) * 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
SE8702550D0 (sv) * 1987-06-18 1987-06-18 Anders Grubb Cysteinproteashemmare
JPH0822874B2 (ja) 1987-06-19 1996-03-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 新種の低カロリータンパク甘味料
EP0315574A3 (de) * 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US4963655A (en) * 1988-05-27 1990-10-16 Mayo Foundation For Medical Education And Research Boron analogs of amino acid/peptide protease inhibitors
US5106948A (en) * 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (de) * 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
ZA897514B (en) * 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
US4997929A (en) * 1989-01-05 1991-03-05 Synergen, Inc. Purified ciliary neurotrophic factor
US4959179A (en) * 1989-01-30 1990-09-25 Lever Brothers Company Stabilized enzymes liquid detergent composition containing lipase and protease
JP2701932B2 (ja) * 1989-04-10 1998-01-21 サントリー株式会社 タンパク質分解酵素阻害剤
US5030378A (en) * 1990-01-02 1991-07-09 The Procter & Gamble Company Liquid detergents containing anionic surfactant, builder and proteolytic enzyme
WO1991013904A1 (en) 1990-03-05 1991-09-19 Cephalon, Inc. Chymotrypsin-like proteases and their inhibitors
GB9017694D0 (en) * 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
EP0478050A1 (en) * 1990-09-24 1992-04-01 Unilever N.V. Detergent composition
GB9024129D0 (en) * 1990-11-06 1990-12-19 Thrombosis Research Trust Inhibitors and substrates of thrombin
JP2703408B2 (ja) 1990-12-28 1998-01-26 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
AU667463B2 (en) * 1990-12-28 1996-03-28 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
JPH06504547A (ja) * 1990-12-28 1994-05-26 ジョージア・テック・リサーチ・コーポレーション ペプチドケトアミド、ケト酸およびケトエステル
EP0511456A1 (en) * 1991-04-30 1992-11-04 The Procter & Gamble Company Liquid detergents with aromatic borate ester to inhibit proteolytic enzyme
DE69209500T2 (de) * 1991-04-30 1996-10-31 Procter & Gamble Gerüstsubstanzhaltige flüssigwaschmittel mit borsäure-polyolkomplex zur ptoteolytischen enzyminhibierung
BR9205958A (pt) * 1991-04-30 1994-09-27 Procter & Gamble Detergentes líquidos com ácido aril borônico
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
CA2133658A1 (en) * 1992-04-16 1993-10-28 Peter R. Bernstein Heterocyclic derivatives
DE69314169T2 (de) * 1992-04-16 1998-01-15 Zeneca Ltd Peptide mit eine alphaaminoboronaire gruppe and ihre verwendung als elastasehemmer
DE69217935T2 (de) 1992-08-14 1997-10-09 Procter & Gamble Alpha-aminoborsäurehaltige flüssige Waschmittel
EP0684829A4 (en) 1993-02-10 1997-05-21 Harvard College THE ROLE OF ATP-UBIQUITIN-DEPENDENT PROTEOLYSIS IN MHC-1 DEPENDENT ANTIGENT PRESENTATION AND RELATED INHIBITORS.
US5384410A (en) * 1993-03-24 1995-01-24 The Du Pont Merck Pharmaceutical Company Removal of boronic acid protecting groups by transesterification
DE4311835A1 (de) * 1993-04-07 1994-10-13 Boehringer Ingelheim Int Verfahren zur Inhibierung der Transkription von Genen
US5424904A (en) 1993-10-04 1995-06-13 Taylor, Sr.; Thomas T. Circuit for electrically controlled intermittent motion
IL111176A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) * 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US5574017A (en) 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) * 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US5550262A (en) * 1994-11-14 1996-08-27 Cephalon, Inc. Multicatalytic protease inhibitors
US6699835B2 (en) * 2001-01-25 2004-03-02 The United States Of America As Represented By The Department Of Health And Human Services Formulation of boronic acid compounds
EP2377868A1 (en) * 2004-03-30 2011-10-19 Millennium Pharmaceuticals, Inc. Synthesis of Bortezomib

Also Published As

Publication number Publication date
CA2203936C (en) 2005-04-12
NL300151I2 (nl) 2004-09-01
US20070282100A1 (en) 2007-12-06
AU710564B2 (en) 1999-09-23
NO971929D0 (no) 1997-04-25
MX9703063A (es) 1998-07-31
EP1312609A1 (en) 2003-05-21
EP1997823A1 (en) 2008-12-03
EP0788360A1 (en) 1997-08-13
US6066730A (en) 2000-05-23
DE69534727T2 (de) 2006-09-14
AU4139896A (en) 1996-05-23
IL115790A0 (en) 1996-01-19
HK1002059A1 (en) 1998-07-31
IL133831A0 (en) 2001-04-30
US6297217B1 (en) 2001-10-02
NZ296717A (en) 1999-11-29
EP1627880B1 (en) 2008-10-15
DE69530936D1 (de) 2003-07-03
US8003791B2 (en) 2011-08-23
CA2203936A1 (en) 1996-05-09
KR970706824A (ko) 1997-12-01
DE122004000025I1 (de) 2004-09-30
US20020173488A1 (en) 2002-11-21
US6548668B2 (en) 2003-04-15
CA2496538C (en) 2011-08-02
WO1996013266A1 (en) 1996-05-09
ATE411324T1 (de) 2008-10-15
US20090247731A1 (en) 2009-10-01
ES2314540T3 (es) 2009-03-16
DK0788360T3 (da) 2003-09-22
NO2004004I1 (no) 2004-08-06
FR04C0014I1 (enExample) 2004-09-17
US5780454A (en) 1998-07-14
FI120974B (fi) 2010-05-31
US7119080B2 (en) 2006-10-10
CN1168633A (zh) 1997-12-24
FI114801B (fi) 2004-12-31
FI971746A0 (fi) 1997-04-23
EP1312609B1 (en) 2005-12-28
US6617317B1 (en) 2003-09-09
EP0788360B3 (en) 2009-08-12
IL137726A (en) 2004-08-31
PT1627880E (pt) 2009-01-23
DE69534727D1 (de) 2006-02-02
DE69535866D1 (de) 2008-11-27
ES2199257T7 (es) 2010-03-31
US6083903A (en) 2000-07-04
KR100398944B1 (ko) 2004-06-04
ATE241631T1 (de) 2003-06-15
DK0788360T5 (da) 2017-09-18
NZ337211A (en) 2000-12-22
CY2484B1 (en) 2005-06-03
US20150072942A1 (en) 2015-03-12
ATE314378T1 (de) 2006-01-15
LU91083I2 (fr) 2004-08-09
US8378099B2 (en) 2013-02-19
PT788360E (pt) 2003-10-31
JPH10510245A (ja) 1998-10-06
IL115790A (en) 2002-12-01
FR04C0014I2 (enExample) 2005-05-21
PT1312609E (pt) 2006-05-31
IL137726A0 (en) 2001-10-31
CN1305475C (zh) 2007-03-21
DK1627880T3 (da) 2008-12-08
FI971746L (fi) 1997-06-06
EP0788360A4 (en) 1998-05-06
US7531526B2 (en) 2009-05-12
ES2199257T3 (es) 2004-02-16
DK1312609T3 (da) 2006-05-15
EP0788360B1 (en) 2003-05-28
US6747150B2 (en) 2004-06-08
FI20041415L (fi) 2004-11-03
NO310558B1 (no) 2001-07-23
JP3717934B2 (ja) 2005-11-16
AU710564C (en) 1996-05-23
NO2004004I2 (no) 2007-09-10
US20110306560A1 (en) 2011-12-15
DE122004000025I2 (de) 2006-09-07
DE69530936C5 (de) 2007-02-22
CH0788360H1 (de) 2006-03-15
US20030199561A1 (en) 2003-10-23
ES2254803T3 (es) 2006-06-16
NO971929L (no) 1997-06-12
US20060122390A1 (en) 2006-06-08
US20080132678A1 (en) 2008-06-05
EP1627880A1 (en) 2006-02-22
US20130310320A1 (en) 2013-11-21
CA2496538A1 (en) 1996-05-09
CN101077875A (zh) 2007-11-28
CN101077875B (zh) 2011-01-26
US6465433B1 (en) 2002-10-15
NL300151I1 (nl) 2004-08-02
HK1087714A1 (en) 2006-10-20
US20040167332A1 (en) 2004-08-26
LU91083I9 (enExample) 2018-12-28
DE69530936T2 (de) 2004-02-26
IL133831A (en) 2004-03-28
DE69530936T3 (de) 2010-08-26

Similar Documents

Publication Publication Date Title
TW318850B (enExample)
CN111801327B (zh) 苯甲酰胺化合物
CA2994404C (en) Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof
TW449590B (en) New arylglycinamide derivatives, processes for the manufacture thereof and pharmaceutical compositions containing these compounds
KR880011199A (ko) 신규 펩타이드 화합물, 그의 제조방법 및 그를 함유하는 약학적 조성물
TW201141480A (en) Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
US20040167337A1 (en) 2-{[n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl}-amino}-alkylboronic acid derivatives
JP4144811B2 (ja) ペプチジル−２−アミノ−１−ヒドロキシアルカンスルホン酸システインプロテアーゼインヒビター
JP6532515B2 (ja) 新規な含窒素化合物もしくはその塩またはそれらと金属との錯体
AU621041B2 (en) Beta-aminoethyl-substituted compounds and halo- azido- and phthalimido-ethyl-substituted phenyl intermediates
JP2017512812A (ja) 複素環によって構成されるトリペプチドエポキシケトン化合物、並びにその作製方法及び使用
JP2000517305A (ja) Ｎ―［ｎ―ｎ―（４―（ピペリジン―４―イル）ブタノイル）―ｎ―エチルグリシル］化合物の安定な非吸湿性結晶形
Ugwu et al. Synthesis and biological applications of hydroxamates
JP7658627B2 (ja) ホウ素中性子捕捉療法用の腫瘍組織を短時間で選択的ないし局所的に標的化できる集積性ボロン１０薬剤
JPH06504301A (ja) キレート化剤
WO2012080260A1 (en) Dimeric iap inhibitors
SE436027B (sv) Nya estrar av kvarternera ammoniumsalter med antikolinerg anti-sekretorisk verkan och farmaceutiska kompositioner innehallande dessa salter
JP2023538768A (ja) 緑膿菌病原性因子ＬａｓＢの阻害剤
WO2007005491A1 (en) Hydrazide conjugates as imaging agents
WO2011106721A1 (en) Flurbiprofen analogs and methods of use in treating cancer
CN114126616A (zh) Bcl-2抑制剂的纳米颗粒制剂
WO2005027856A2 (en) Inhibitors of anthrax lethal factor
CA2405871A1 (en) 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives
US3804820A (en) N-(substituted-alpha-penicilloyl)-amino carboxylic acids
JPH0651677B2 (ja) ジペプチド誘導体及びその製法並びに用途

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent